Biogen, Eisai Present Five-Year Lecanemab Extension Data at CTAD
The data cover continuous lecanemab treatment in the five-year Clarity AD extension among patients with early Alzheimer's disease.
The data cover continuous lecanemab treatment in the five-year Clarity AD extension among patients with early Alzheimer's disease.